{"filings":[{"id":499359,"accession_number":"0000064803-26-000082","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2026-05-18T20:13:58+00:00","items":["5.02","5.07"],"status":"ready","headline":"CVS shareholders approve 2026 incentive plan, re-elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["13 directors elected; all management proposals passed including 2026 ICP approval.","2026 Incentive Compensation Plan replaces expiring 2017 plan; effective for awards after May 14, 2026.","Advisory say-on-pay passed with ~94% of votes cast (excluding broker non-votes).","Ernst & Young ratified as independent auditor for 2026 with 1.12B votes for.","Stockholder proposal to reduce written consent threshold failed with ~40% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98314,"accession_number":"0000064803-26-000051","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Q1 revenue $100.4B (+6.2% YoY); raises FY26 EPS guidance to $7.30-7.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.30 vs $1.41 YoY; Adjusted EPS $2.57 vs $2.25 YoY.","Health Care Benefits MBR improved to 84.6% (down 270 bps); adjusted op income up 52.6% to $3.04B.","Health Services segment revenue $48.2B (+11.0%) but adj op income -7.1% on client price improvements.","Pharmacy & Consumer Wellness adj op income -8.8% due to reimbursement pressure and seasonal illness decline.","FY26 guidance raised: GAAP EPS $6.24-6.44 (from $5.94-6.14); cash from ops at least $9.5B (from $9.0B)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":100426000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113701,"accession_number":"0000064803-26-000017","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CVS Health elects former Elevance CFO John Gallina to board, effective March 19, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John E. Gallina, age 66, former EVP and CFO of Elevance Health (NYSE: ELV), elected to CVS Health Board.","Gallina served as Elevance CFO from June 2016 to Nov 2023 and as EVP/Advisor to CEO until May 2024.","Appointed to Audit Committee and designated an audit committee financial expert under SEC rules.","Board determined Gallina to be independent under NYSE rules; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113700,"accession_number":"0000064803-26-000009","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q4 revenue $105.7B (+8.2%); adj. EPS $1.09 vs $1.19; 2026 adj. EPS guide $7.00-$7.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue record $402.1B (+7.8%); GAAP EPS $1.39 (incl. $5.7B goodwill impairment), Adj. EPS $6.75 (+24.5%).","Q4 Health Care Benefits segment adj. op. loss ($676M) widened from ($439M) on IRA Medicare Part D seasonality.","Pharmacy & Consumer Wellness Q4 adj. op. income $1,911M (+8.7%) on higher prescription volume including Rite Aid acquisitions.","2026 guidance: GAAP EPS $5.94-$6.14; Adj. EPS $7.00-$7.20; cash flow from operations at least $9.0B (down from prior $10.0B).","Medical membership 26.6M, down 0.5M YoY; days claims payable 38.9 (down 3.6 days from Q3)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":402067000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130088,"accession_number":"0000064803-25-000082","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CVS Health raises 2025 guidance and initiates 2026 outlook with mid-teens EPS CAGR target","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2025 revenue guidance raised to at least $400B; Adjusted EPS raised to $6.60-$6.70 from $6.55-$6.65.","2026 full-year guidance: revenue at least $400B, Adjusted EPS $7.00-$7.20, cash flow from operations at least $10B.","Commits to mid-teens Adjusted EPS CAGR through 2028, driven by margin recovery at Aetna and growth across segments.","Announces 'Engagement as a Service' open consumer platform using AI to integrate healthcare experiences.","Reaffirms 2025 cash flow from operations of $7.5B-$8.0B; 2026 outlook at least $10B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130087,"accession_number":"0001193125-25-289805","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health appoints CEO David Joyner as Chair of the Board effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joyner, President & CEO since Oct 2024, will also serve as Board Chair starting Jan 1, 2026.","Michael Mahoney continues as Lead Independent Director; Roger Farah remains on the Board.","Board cites Joyner's nearly 40 years of healthcare experience and operational improvements.","Joyner leads over 300,000 colleagues; Farah says 'bullish on future' under combined roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130086,"accession_number":"0000064803-25-000036","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q3 GAAP EPS loss of $3.13 on $5.7B goodwill impairment; raises FY2025 adjusted EPS guide to $6.55-$6.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues of $102.9B, up 7.8% YoY; GAAP diluted loss per share of $3.13 includes $5.7B goodwill impairment charge.","Adjusted EPS of $1.60, above prior year $1.09; FY2025 Adjusted EPS guidance raised to $6.55-$6.65 from $6.30-$6.40.","Health Care Benefits segment MBR improved to 92.8% from 95.2%; adjusted operating income of $314M vs loss of $924M in prior year.","Health Services adjusted operating income down 7.0% to $2.05B; Pharmacy & Consumer Wellness down 7.4% to $1.478B.","Aetna Medicare Advantage Star Ratings: >81% of members in 4-star+ plans; Caremark contract wins of ~$6.0B with high retention."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":296374000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146674,"accession_number":"0001193125-25-211349","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS subsidiary Omnicare files Chapter 11 bankruptcy after excessive court damages ruling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Omnicare, a wholly owned CVS subsidiary, voluntarily initiated Chapter 11 proceedings on Sept. 22, 2025.","Filing triggered by a U.S. District Court (SDNY) ruling imposing excessive monetary damages for alleged pharmacy law violations.","Omnicare obtained $110M debtor-in-possession financing from a third party to support operations during the process.","Company intends to pursue a standalone restructuring or sale strategy while continuing pharmacy services without disruption.","No allegations of patient harm; Omnicare President cited the penalty as constitutionally excessive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146673,"accession_number":"0001193125-25-181862","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health issues $4B in senior notes across four tranches with maturities 2032-2065","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$750M 5.000% Senior Notes due 2032, $1.5B 5.450% Senior Notes due 2035.","$1.25B 6.200% Senior Notes due 2055, $500M 6.250% Senior Notes due 2065.","Net proceeds ~$3.958B after underwriting discounts and estimated offering expenses.","Issued August 15, 2025; underwritten by Barclays, J.P. Morgan, and Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146672,"accession_number":"0000064803-25-000023","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q2 adj EPS $1.81; raises FY25 adj EPS outlook to $6.30-6.40, cuts GAAP view on litigation charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $98.9B (+8.4% YoY); GAAP EPS $0.80 vs $1.41; adj EPS $1.81 vs $1.83.","Recorded $833M litigation charges and $471M premium deficiency reserve in Medicare Advantage.","FY25 GAAP EPS guidance lowered to $3.84-3.94 from $4.23-4.43; adj EPS raised to $6.30-6.40 from $6.00-6.20.","Aetna MBR 89.9% vs 89.6% with premium deficiency impact; medical membership 26.7M down 358k sequentially.","Agreed to acquire certain Rite Aid prescription files and stores; cash flow from operations guided to at least $7.5B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":193503000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165075,"accession_number":"0000064803-25-000015","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CVS Health annual meeting results: all 13 directors elected; say-on-pay passes with 59% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; votes ranged from 926M to 1.007B in favor, with broker non-votes of 111M.","Advisory say-on-pay approved: 597.9M for, 413.3M against, 2.8M abstain.","Ratification of Ernst & Young as auditor for 2025 approved: 1.104B for, 19.2M against.","Stockholder proposal to lower threshold for acting by written consent failed: 431.2M for, 577.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165074,"accession_number":"0000064803-25-000012","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q1 Adj EPS $2.25 vs $1.31 YoY; raises FY25 Adj EPS guidance to $6.00-$6.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $94.6B, up 7.0% YoY; GAAP diluted EPS $1.41, Adjusted EPS $2.25.","Operating income $3.374B vs $2.271B YoY; adjusted operating income $4.579B vs $2.957B.","Full-year 2025 guidance: GAAP diluted EPS revised to $4.23-$4.43 from $4.58-$4.83; Adjusted EPS raised to $6.00-$6.20 from $5.75-$6.00.","CVS Health to exit individual exchange business; introduces Aetna solutions and CVS Caremark GLP-1 formulary update.","Cash flow from ops $4.6B in Q1; FY25 CF guidance raised to ~$7.0B from ~$6.5B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":94588000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165073,"accession_number":"0001193125-25-075089","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CVS Health appoints new CFO and CMO; affirms FY2025 guidance will meet or exceed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brian Newman named EVP & CFO effective May 12; base salary $1M, target bonus 150% of salary.","Current CFO Tom Cowhey steps down May 12, becomes strategic advisor to CEO until departure.","Amy Compton-Phillips appointed EVP & Chief Medical Officer, effective May 19.","Based on YTD results through Feb, CVS expects full-year 2025 results to meet or exceed prior guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182777,"accession_number":"0000064803-25-000006","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q4 revenue up 4.2% to $97.7B, adjusted EPS falls 44% to $1.19; FY25 guidance below consensus","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.30 (down $0.28 YoY); adjusted EPS $1.19 (down $0.93 YoY) on Health Care Benefits weakness.","Full-year 2024 total revenues $372.8B (+4.2% YoY); GAAP diluted EPS $3.66, adjusted EPS $5.42.","Health Care Benefits segment hurt by continued utilization pressure and unfavorable Medicare Advantage star ratings.","2025 guidance: GAAP diluted EPS $4.58-$4.83; adjusted EPS $5.75-$6.00; cash flow from ops ~$6.5B.","Pharmacy & Consumer Wellness segment showed growth, but overall earnings pressured by insurance challenges."],"consensus_eps_estimate":null,"consensus_eps_actual":3.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":372809000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199354,"accession_number":"0001193125-24-279907","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health announces early results and pricing of $1.774B debt tender offer; early settlement Dec 18","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maximum tender amount $1.774B; notes tendered exceeded cap; no further purchases expected after Dec 18.","Total consideration per $1,000 par: 2.700% notes due 2040 at $685.54; 3.875% notes due 2047 at $750.06.","Early settlement Dec 18; proration applied: 4.125% notes due 2040 accepted at ~57.5% of tendered; six series 0%.","Dealer managers Barclays and Mizuho; tender agent D.F. King; notes issued by CVS and Aetna Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199353,"accession_number":"0001193125-24-274362","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health issues $3.0B in junior subordinated notes across two tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.25B of 7.000% Fixed-to-Fixed Rate Series A Junior Subordinated Notes due 2055.","Issued $750M of 6.750% Fixed-to-Fixed Rate Series B Junior Subordinated Notes due 2054.","Notes offered under existing shelf registration; use of proceeds not specified.","Supplemental indentures filed with the SEC as Exhibits 4.2 and 4.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199352,"accession_number":"0001193125-24-272865","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health completes tender offer for $226M of 4.100% Senior Notes due 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tendered $225,979,000 principal amount of 4.100% Senior Notes due 2025 (out of $950,087,000 outstanding) plus $5,000 via guaranteed delivery.","Settlement expected on December 11, 2024.","Purchase to be funded with proceeds from new junior subordinated notes (7.000% Series A due 2055 and 6.750% Series B due 2054).","Total tender capped at $2B across this Any-and-All and a concurrent Maximum Tender Offer for other notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199351,"accession_number":"0001193125-24-272437","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health prices tender offer for $950M 4.100% Senior Notes due Mar 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal outstanding $950,087,000 of 4.100% Senior Notes due March 25, 2025.","Total consideration set at $998.22 per $1,000 principal, plus accrued interest.","Reference yield 4.434% based on 3.875% UST due 3/31/2025 plus 25 bps spread.","Settlement expected on December 11, 2024, for notes tendered by Dec 6 deadline.","Tender offer is subject to financing condition; no minimum principal condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199350,"accession_number":"0001193125-24-270867","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health issues $3B junior subordinated notes: 7.0% due 2055, 6.75% due 2054","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.25B of 7.000% Series A Junior Subordinated Notes due 2055 and $750M of 6.750% Series B Junior Subordinated Notes due 2054.","Expected net proceeds ~$2.963B after underwriting discounts and expenses.","Closing expected December 10, 2024; lead underwriters include Barclays, Citigroup, Goldman Sachs.","Registration statement on Form S-3ASR (File No. 333-272200) effective May 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199349,"accession_number":"0001193125-24-268490","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health launches cash tender offers for up to $2B of senior notes; any and all 2025 notes included","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Any and all tender for $950M 4.100% Senior Notes due 2025; fixed spread +25 bps over 3.875% UST due 3/31/2025.","Maximum Tender Offer targets up to $2B aggregate purchase price across 10 series of notes with maturities 2030-2050.","Early tender payment of $30 per $1,000 for Maximum Tender Offer Notes tendered by Dec 13, 2024.","Tender offers conditioned on issuance of new subordinated debt; may be funded with cash if not."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199348,"accession_number":"0001193125-24-260405","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"CVS Health adds four directors, enters pact with Glenview Capital; CEO pay raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board expanded from 12 to 16 with appointments of Leslie Norwalk, Larry Robbins, Guy Sansone, Doug Shulman.","Glenview Capital (Larry Robbins) gets board seats; standstill until 30 days before 2026 director nomination window.","CEO David Joyner's total direct compensation raised to $19M/yr ($1.5M base, $3M bonus target, $14.5M LTI).","Prem Shah (EVP Group President) gets $1.1M base, $1.925M bonus target, $9M LTI; one-time option award $6M.","Tilak Mandadi receives $3M in time-vesting RSUs as retention award; vests over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199347,"accession_number":"0001193125-24-251673","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CVS Health appoints Prem Shah as Group President and Steve Nelson as President of Aetna","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Prem Shah named EVP & Group President, overseeing CVS Caremark, CVS Pharmacy, and Health Care Delivery (Oak Street, Signify).","Steve Nelson named EVP & President of Aetna; previously CEO of ChenMed and UnitedHealthcare.","Both appointments effective November 6, 2024, reporting to CEO David Joyner.","Shah most recently EVP, Chief Pharmacy Officer and President of Pharmacy & Consumer Wellness.","Nelson's managed care experience expected to drive Aetna growth and profitability improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199346,"accession_number":"0000064803-24-000033","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q3 GAAP EPS $0.07, Adjusted EPS $1.09; records $1.1B premium deficiency reserve","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $95.4B (+6.3% YoY); GAAP diluted EPS $0.07 vs $1.75 prior year.","Adjusted EPS $1.09 vs $2.21 prior year; operating income $832M down from $3.69B.","Health Care Benefits segment recorded ~$1.1B premium deficiency reserves ($0.63/share) for Medicare and individual exchange.","Year-to-date cash flow from operations $7.2B; CEO highlights strong Health Services and Pharmacy segments but challenges in Health Care Benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":275099000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199345,"accession_number":"0001193125-24-239193","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["2.02","7.01","5.02","9.01"],"status":"ready","headline":"David Joyner named CVS Health CEO replacing Karen Lynch; preliminary Q3 EPS guide weak","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Joyner appointed President and CEO effective Oct. 17, 2024, succeeding Karen Lynch who resigned.","Roger Farah elevated to Executive Chairman of the Board.","Preliminary Q3 2024 GAAP diluted EPS $0.03-$0.08; adjusted EPS $1.05-$1.10.","Results include $1.1B premium deficiency reserve charge and $1.2B restructuring charge.","MBR expected ~95.2%; prior guidance withdrawn due to elevated medical cost trends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215386,"accession_number":"0000064803-24-000028","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q2 adj EPS $1.83 vs $2.21 YoY; cuts FY2024 adj EPS guidance to $6.40-$6.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $91.2B, up 2.6% YoY; GAAP diluted EPS $1.41 vs $1.48, Adjusted EPS $1.83 vs $2.21.","Operating income $3.045B vs $3.234B; adjusted operating income $3.744B vs $4.481B, driven by Health Care Benefits segment pressure.","FY2024 GAAP EPS guidance lowered to $4.95-$5.20 from at least $5.64; cash flow from ops guided to ~$9B from at least $10.5B.","Health Care Benefits segment faces continued utilization pressure and unfavorable Medicare Advantage star ratings impact.","CEO announces leadership changes in Health Care Benefits segment; strong performance in Health Services and Pharmacy & Consumer Wellness."],"consensus_eps_estimate":null,"consensus_eps_actual":2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":179671000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234699,"accession_number":"0000064803-24-000019","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CVS shareholders approve 33.5M share increase to equity plan; all directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2017 ICP, increasing authorized shares by 33.5 million for future awards.","All 12 director nominees elected, including CEO Karen S. Lynch, with >85% support from votes cast.","Advisory vote on named executive officer compensation passed (818M for, 139M against, excluding broker non-votes).","Ratification of Ernst & Young as independent auditor for 2024 approved (1.083B for, 22.9M against).","Four stockholder proposals (worker rights, majority vote, golden parachute, director time disclosure) all rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234698,"accession_number":"0001193125-24-135296","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health issues $5B in senior notes across five tranches with rates 5.400%-6.050%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1B at 5.400% due 2029, $1B at 5.550% due 2031, $1.25B at 5.700% due 2034.","Also issued $750M at 6.000% due 2044 and $1B at 6.050% due 2054; total $5.0B.","Notes sold under existing shelf registration (S-3ASR filed May 2023) and senior indenture.","Proceeds not specified; typical for general corporate purposes, debt refinancing, or capex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234697,"accession_number":"0001193125-24-134280","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVS Health issues $5.0B in senior notes across five tranches with rates 5.4%-6.05%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $5.0B; net proceeds ~$4.95B after underwriting discounts and expenses.","Tranches: $1B 5.400% due 2029, $1B 5.550% due 2031, $1.25B 5.700% due 2034, $750M 6.000% due 2044, $1B 6.050% due 2054.","Closing expected May 9, 2024, subject to customary conditions.","Underwriters include BofA Securities, Barclays, Goldman Sachs, J.P. Morgan, and Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234696,"accession_number":"0000064803-24-000015","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Health Q1 GAAP EPS $0.88 vs $1.65; FY2024 guidance slashed on Medicare pressure","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues rose 3.7% to $88.4B; GAAP diluted EPS $0.88 vs $1.65; adjusted EPS $1.31 vs $2.20.","Operating income fell to $2.3B from $3.4B; Health Care Benefits segment pressured by Medicare utilization.","FY2024 guidance cut: GAAP EPS at least $5.64 (from $7.06); Adj EPS at least $7.00 (from $8.30).","Q1 cash flow from operations $4.9B; FY guidance reduced to at least $10.5B from $12.0B.","CEO cites Medicare Advantage challenges; expects elevated cost trends to persist through 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":88437000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252556,"accession_number":"0000064803-24-000009","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CVS Health reiterates FY2024 guidance: GAAP EPS ≥$7.06, adjusted ≥$8.30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed FY2024 GAAP diluted EPS guidance of at least $7.06.","Reaffirmed FY2024 Adjusted EPS guidance of at least $8.30.","Reaffirmed FY2024 cash flow from operations guidance of at least $12.0 billion.","CFO Tom Cowhey to discuss business trends at March 5 webcast.","Guidance unchanged; no new financial information provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252555,"accession_number":"0000064803-24-000006","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVS Q4 revenue $93.8B (+11.9% YoY), adj. EPS $2.12; FY2024 adj. EPS guidance cut to $8.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $93.8B (+11.9% YoY); GAAP diluted EPS $1.58, adjusted EPS $2.12.","Full-year 2023 revs $357.8B (+10.9%), GAAP EPS $6.47, adj. EPS $8.74; ops cash flow $13.4B.","FY2024 guidance revised: adj. EPS at least $8.30 (from $8.50), GAAP EPS at least $7.06, ops cash flow $12.0B.","Quarterly dividend raised 10% effective Feb 1, 2024; $3.1B returned via dividends in 2023.","Launched CVS CostVantage, Caremark TrueCost pricing models and CVS Healthspire segment for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":6.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":357776000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252554,"accession_number":"0000947871-24-000009","cik":64803,"company_name":"CVS HEALTH Corp","ticker":"CVS","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"CVS names Tom Cowhey CFO, Mike Pykosz President of Health Care Delivery; reaffirms FY2023 and FY2024 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas F. Cowhey appointed EVP and CFO effective Jan 5, 2024; receives $1M base salary, target cash incentive 150%, and $5.5M equity award.","Shawn Guertin steps down as CFO and President of Health Services due to family health reasons; will leave CVS on May 31, 2024.","Mike Pykosz appointed President of Health Care Delivery; he was CEO of Oak Street Health and interim lead since Oct 13, 2023.","Reaffirms 2023 GAAP EPS guidance $6.37-$6.61, Adjusted EPS $8.50-$8.70 (expects upper half); 2024 guidance at least $7.26 GAAP, $8.50 Adjusted.","Expects Medicare Advantage membership growth of at least 800k in 2024; enrollment exceeded expectations during annual enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117474625894.02037,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}